Israeli generic drug giant Teva to buy Cephalon

May 02, 2011

Teva Pharmaceutical Industries, the world's largest generic drug maker, will buy US biopharma firm Cephalon in a $6.8 billion deal, the companies said in a joint statement Monday.

Teva, headquartered in , said the acquisition would help to expand and diversify it products, including into new areas such as .

The friendly takeover comes after Cephalon last month rejected a hostile $5.7 billion bid from Canadian firm Valeant.

Teva offered $81.50 in cash for all of Cephalon's shares outstanding, representing a 39 percent premium on Cephalon's share value at the end of March, before Valeant launched its .

The Teva offer values Cephalon at $6.8 billion, including debt.

Both companies' board of directors unanimously agreed to the deal.

Teva said the acquisition was not conditioned on obtaining financing and was expected to be completed in the third quarter of 2011.

"The transaction reinforces Teva's long-term strategy of building out its branded and specialty pharmaceuticals business through diversification and expansion of the company's product portfolio and pipeline," the Israeli group said.

The combined company will become "a leader in specialty pharma" and will have a "sizable" branded portfolio that represents about $7 billion in sales, it said.

Founded in 1987, Cephalon had $2.8 billion in revenue in 2010. The company employs 4,000 people worldwide and specializes in cancer and pain treatments.

Explore further: Risk of antibiotic overuse in aged care settings

add to favorites email to friend print save as pdf

Related Stories

Cephalon biotech rejects $5.7 billion Valeant bid

Apr 06, 2011

US biotech group Cephalon has rejected a hostile, $5.7 billion acquisition bid from its Canadian rival Valeant, which counter-attacked by seeking to replace the firm's board of directors.

Roche to take over Genentech for $47 billion

Mar 12, 2009

(AP) -- Swiss pharmaceutical giant Roche said Thursday it has agreed to buy California-based Genentech for $46.8 billion in a takeover described as the largest in Swiss corporate history.

EMC counters NetApp bid for Data Domain

Jun 01, 2009

US computer storage giant EMC Corp. offered 1.8 billion dollars on Monday for Data Domain in a bid to counter a rival offer for the data storage company from NetApp.

EMC raises offer for Data Domain

Jul 06, 2009

Computer storage giant EMC raised its offer to purchase data storage firm Data Domain on Monday in a bid to top a rival offer for the company by data management firm NetApp.

Genzyme board rejects Sanofi bid

Aug 30, 2010

The board of directors at US biotechnology firm Genzyme has unanimously rejected an 18.5-billion-dollar takeover offer from French pharmaceutical giant Sanofi-Aventis, Genzyme said Monday. ...

Recommended for you

Supermaterial gives rejected drugs a new chance

14 hours ago

More than 80 percent of all drug candidates in the pharma R&D suffer from poor solubility and are therefore rejected early in the drug discovery process. Now Uppsala University researchers show that the new ...

Risk of antibiotic overuse in aged care settings

Jul 21, 2014

Antibiotics are being overused in residential aged care facilities (RACFs), and more integrated efforts to improve antibiotic prescribing practices need to be introduced, researchers say. 

Ruconest approved for rare genetic disease

Jul 17, 2014

(HealthDay)—Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal ...

NIH system to monitor emerging drug trends

Jul 17, 2014

An innovative National Drug Early Warning System (NDEWS) is being developed to monitor emerging trends that will help health experts respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased ...

User comments : 0